Yan Li1, Laleh Jalilian1, Youngho Seo1, Dave Wilson1, Miguel Pampaloni1, Henry Vanbrocklin1, Michael Prados2, Sarah J. Nelson1, 3
1Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, United States; 2Department of Neurosurgery, University of California, San Francisco, CA, United States; 3Department of Bioengineering and Therapeutic sciences, University of California, San Francisco, CA, United States
The purpose of this study was to assess the correlation between18F-fluoromisonidazole PET (18F-FMISO-PET) parameters and those from MRI, including perfusion-weighted imaging (PWI), diffusion-weighted imaging (DWI) and magnetic resonance spectroscopic imaging (MRSI) in patients with GBM for whom progression was suspected. Three patients diagnosed with glioblastoma Multiforme (GBM) were studied at the time of suspected progression. The relationship of the PET parameters to the MRI-defined abnormalities was examined. Elevated CBV and PH values were detected in a region that corresponded with T/B>=1.1.
Keywords